Investing in firms which develop and sell life-changing drugs has been a rewarding trade over the past five years. The MSCI World Healthcare index has returned 73%, according to FE Fundinfo, nearly twice the return of the FTSE 100 (42%) in dollar terms.
Over the long term, those kind of returns are an incredibly powerful driver for wealth creation in an investment portfolio, although like any sector there will be good and bad years. There is also no guarantee returns from the healthcare sector will always be that strong.
If you think that 73% is a decent return, there is one stock which has outperformed the MSCI index 11 times over – Eli Lilly (LLY:NYSE), which has a duopoly with Novo Nordisk (NVO:NYSE) in the provision of weight-loss drugs and has returned 806% in five years, the kind of gains most investors can only dream of achieving.
A study published in the JAMA Internal Medicine journal recently found Eli Lilly’s Mounjaro was more successful at helping users lose weight than Novo Nordisk’s Ozempic (known as Wegovy in the UK).
Does that explain why Eli Lilly has eclipsed Novo Nordisk on the stock market, with the latter ‘only’ achieving 350% returns over the past five years?
Whether that is purely a coincidence or not, demand currently exceeds supply for weight-loss drugs from both companies. This situation puts pressure on Eli Lilly and Novo Nordisk to complete investments in additional production capacity so they can get more product onto the market.
It doesn’t look like a coincidence that their shares have stumbled given the supply constraints: Eli Lilly’s share price has been flat in recent months, while Novo Nordisk’s shares have eased back.
WHAT HAPPENS NEXT?
Investors can see potential challengers on the horizon as the next 12 to 24 months could bring Phase Three trial data for rival products. Drugs have to go through multiple tests before the regulator will consider them for commercial use, and Phase Three trials are the last stage of testing before submission to the authorities for approval.
So many names are trying to get in on the game, from small biotechnology companies to large players such as Amgen (AMGN:NASDAQ), AstraZeneca (AZN) and Pfizer (PFE:NYSE).
Eli Lilly and Novo Nordisk have enjoyed massive success commercially and on the stock market because they found a way to make weight-loss drugs more effective. The downside is users can experience nasty side-effects such as nausea, which has led people to come off the drugs.
The next phase in the weight-loss drug boom is for scientists to find ways to reduce the side-effects. Whoever does crack the magic formula could make a fortune.
BIG MARKET OPPORTUNITY
Greater volumes of weight-loss drugs should bring down prices, yet that should also broaden the potential market as the products become more affordable. It implies the sector still has a large opportunity to make money while at the same time helping to transform people’s lives.
‘It’s human nature that we don’t all want to diet and exercise, it’s not cutting it in terms of the obesity problem we’ve got, and people are getting more obese,’ says Ailsa Craig, joint fund manager of the International Biotechnology Trust (IBT).
That might explain why individuals are looking for a different solution and embracing a weight-loss drug such as Zepbound and Wegovy. They are even more powerful than you think, with far-reaching benefits.
‘It’s not just a lifestyle drug (to lose weight),’ adds Craig. ‘It’s also helping patients because it can reduce heart disease, hypertension, cholesterol, diabetes and kidney disease. All these comorbidities, each of which are separately treated with other drugs, could be prevented if these patients lost weight.’
The benefits go even further. There is the potential to have a weight-loss drug on the market which not only tackles obesity but also helps to reduce alcohol or substance use, and even used on a wider basis such as potentially helping to prevent dementia and improve cognitive function in people with Alzheimer’s disease.
A US study of more than 500,000 people with a history of opioid- and alcohol-use disorder showed those who were separately prescribed weight-loss drugs experienced up to 50% lower rates of overdose and intoxication than those without the treatment, according to the Financial Times.
THE INVESTMENT THEME HASN’T PLAYED OUT
This broad spectrum of applications explains why weight-loss drugs have been one of the hottest investment themes in recent years, second only to AI (artificial intelligence).
No-one knows who the big players of tomorrow will be, and investing in the biotechnology and pharmaceutical industries comes with considerable risk which is why investors typically prefer to use a diversified specialist fund rather than betting everything on a single company.
Just because Eli Lilly and Novo Nordisk’s share price rallies have lost steam doesn’t mean the weight-loss drug theme has fully played out.
It’s perfectly normal to see a pause as the industry transitions to its next phase. We’re definitely at that stage now, but what’s certain is the space is getting even more interesting rather than fading away.
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
magazine
